Contribution
It is a pleasure to see you in the Chair, Sir John, and to follow the right hon. Member for Tatton (Esther McVey). We chair the all-party parliamentary group on pandemic response and recovery, which we set up after the pandemic, partly because, as the right hon. Member has just said, of failures during the pandemic. We wanted to investigate what was happening afterwards and make recommendations to improve the process.
We were left confounded by trying to get information regularly from the MHRA, which is a very strange beast indeed. It is an arm’s length regulator, which is sensible, but it is funded by the pharmaceutical industry. That inevitably leads to a belief, and it seems to be the case in practice, that the MHRA is working not on behalf of the public and patients, but on behalf of the pharmaceutical industry. That is further exacerbated by its secretive ways. It has not responded in the past to freedom of information requests and has not responded adequately to our requests for further information about how it is proceeding, assessing and investigating yellow card complaints. So it leads me to ponder whether it should continue to exist. The questions asked by the hon. Member for Camborne and Redruth (Perran Moon) are the right questions: can it be improved? Will it reform itself? Can it be reformed by the Government and improve? From my experience over the last four or five years, it cannot.
We therefore have to ask whether this regulatory quango would be best as an advisory body to the Secretary of State for Health and Social Care, because one problem we have had is getting information out of the MHRA. Although parliamentary democracy is imperfect and sometimes we have difficulties in getting information out of Departments, at least we can get the Secretary of State and the Minister on to the Floor of the House, in front of Select Committees and in debates in Westminster Hall to ask questions directly when things go wrong, which is not possible with the MHRA. So, I have come to the conclusion that there should be a serious investigation and assessment of the MHRA by the Government. Obviously, they would have to look at the evidence, but at the moment I think that they should bring it in as an advisory body. My answer to the question is that it is not reformable as it stands.
I would like to take up one further, rather detailed point that the right hon. Member for Tatton made about her constituent, an elderly lady, who died. When the very quick—and, in the final analysis, effective—tests on the vaccines were carried out, as is often the case, elderly people were either not present or under-represented in those tests. That is not unreasonable in itself, but it means that the MHRA should spend more time looking at what has happened when there are adverse events and deaths following injections. Those people were not really tested when the vaccine itself was tested. But the MHRA has done completely the opposite: when there have been adverse events and deaths, it has effectively ignored them and not properly assessed and investigated them.
There are a number of simple points I want to make, although there are people who want to speak. When I looked at the debate we had on 16 January last year, one thing I had forgotten that surprised me was that a number of hon. Members blamed the fact that we had left the European Union for the inadequacies of our regulation. That is the exact opposite of the truth. The fact is that by taking regulation in-house, we should have been able to be more effective. When the European Medicines Agency was in charge, we did not know who was regulating our medicines and devices, because those devices and medicines could be approved anywhere in Europe.
I will finish with a number of questions, but before I get to them there is another case that has not been mentioned before. Voy has put adverts on London buses with the slogan “The Weight is Over”, which is a pun on waiting to get rid of excess weight. The MHRA and the Advertising Standards Agency have found it to be in breach of the regulations. We are not allowed by law in this country to advertise prescription medicines and this is clearly a device to get around that. The MHRA found against it, saying some very strong things in condemnation of those adverts, but what has been the consequence? Zero. It is great to criticise an illegal advert, as found by both regulatory bodies, but what has been the consequence for Voy? Even when the MHRA has assessed things, it has not really pursued it.
I would like to finish with four questions. We do not know how much has been spent on the yellow card system. Will the Minister tell us that, or will he find out? How much is spent on the regulation on devices and medicines? We cannot find that out. How many individual investigations have there been, and how many have led to changes in advice on prescriptions? I would be grateful if the Minister could answer those questions either today or by correspondence.